CA
NZ
UK
AU
IND
US
Clinical data, not sentiment, will decide Acumen Pharmaceuticals (NASDAQ:ABOS) because the company is a clinical-stage biotechnology firm with no approved products and no product revenue. Its entireInvestmentcase rests on whether its lead antibody candidate, sabirnetug, can demonstrate a meaningful clinical benefit in Alzheimer's disease.
Absci (NASDAQ:ABSI) represents an attempt to apply artificial intelligence to one of biology's hardest problems: designing new medicines. Rather than discovering antibodies by screening vast numbers of natural candidates, Absci's platform uses AI models to design new antibody and protein sequences with desired properties, …
Abbott Laboratories (NYSE:ABT) links investors to everyday healthcare innovation because its products touch patients and consumers across the whole spectrum of medicine, from the hospital to the home. It makes continuous glucose monitors worn by people with diabetes, devices that treat heart-rhythm and structural-heart …
AbCellera (NASDAQ:ABCL) offers a different drug-discovery model because it began not as a maker of medicines but as a technology platform that discovers antibodies for others. Using artificial intelligence and high-throughput laboratory techniques, it identifies promising antibody candidates and has historically licensed them to …
Gene therapy could shape Abeona Therapeutics' (NASDAQ:ABEO) story because the company has moved from developing an experimental treatment to selling an approved one, a transition that decides whether years of research turn into a real business. Its product, ZEVASKYN, is a gene therapy for …
AbbVie's (NYSE:ABBV) drug portfolio matters because it's the proof that the company has managed one of the hardest transitions in the pharmaceutical industry: replacing a single dominant product with a broader, growing lineup. For years AbbVie depended on Humira, an immunology treatment that was …
Aardvark Therapeutics' (NASDAQ:AARD) metabolic research matters because it targets conditions where the biology of hunger and metabolism goes wrong, most notably Prader-Willi syndrome, a rare genetic disorder characterized by insatiable appetite that can be life-threatening. But the reason the story matters right now is …
Agilent Technologies (NYSE:A) makes the laboratory instruments, software, and lab services that sit behind much of the analytical work done in pharmaceuticals, diagnostics, and materials science. A stronger-than-expected third quarter and a raised full-year outlook show why this S&P 500 component remains a barometer …
Targeted cancer treatments matter for ADC Therapeutics (NYSE:ADCT) because that's what the company makes: antibody-drug conjugates, or ADCs, a class of therapy designed to attack cancer more precisely than traditional chemotherapy. An ADC links an antibody, which seeks out a specific marker on cancer …
Antibiotic development could shape Acurx Pharmaceuticals (NASDAQ:ACXP) because a single new antibiotic is essentially the whole company. Acurx is a clinical-stage biotechnology firm developing ibezapolstat, an oral antibiotic for Clostridioides difficile infection, a serious bacterial infection of the gut that causes severe diarrhea, can …
Please wait processing your request...